SS-31 shows measurable mitochondrial function improvements within 2–4 weeks, with

SS-31 (elamipretide) targets inner mitochondrial membranes to reduce ischemic injury.

SS-31 dosing for cardioprotection ranges 0.5–5.0 mg/kg based on research

SS-31 dosing ranges from 0.25mg/kg to 0.5mg/kg daily based on

SS-31 cardioprotection results emerge in phases: cellular function improves within

SS-31 (elamipretide) targets mitochondrial cardiolipin to reduce oxidative damage. Current

SS-31 dosage for aging research ranges 5–20mg weekly based on

SS-LUP-332 exercise mimetic effects appear within 2–4 weeks at therapeutic

SS-LUP-332 exercise mimetic activates AMPK pathways without physical exertion —

ARA-290 neuroprotection results timeline expect varies by condition — acute

ARA-290 activates innate repair receptors in neurons, reducing inflammation and

ARA-290 shows promise for neuropathy through innate repair receptor activation,

ARA-290 activates innate repair receptors to accelerate tissue regeneration. Learn

ARA-290 activates innate repair receptors to accelerate tissue regeneration. Learn

ARA-290 dosing for neuroprotection ranges 2–8mg subcutaneous 2–3× weekly, with

ARA-290 tissue repair results typically emerge within 2–4 weeks for

ARA-290 at 4mg subcutaneous three times weekly has shown neuroprotective

ARA-290 shows early neuropathy improvement in 4–8 weeks, with full

ARA-290 dosage for tissue repair ranges 4–8mg per injection, administered

ARA-290 targets innate repair pathways in diabetic neuropathy and retinopathy

SS-31 shows measurable mitochondrial ATP improvements within 7–14 days, structural